ArticleFrontiers in oncology2024

Case report: The effect of second-line vebreltinib treatment on a patient with advanced NSCLC harboring the MET exon 14 skipping mutation after tepotinib treatment.

Siyuan Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.